Clinical Trials
13 trialsNCT07205315 2026-05-27
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Grit Biotechnology
Phase EARLY_PHASE1 Recruiting
NCT07584850 2026-05-13
Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Ruijin Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT04161248 2026-05-12
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Canadian Cancer Trials Group
Phase EARLY_PHASE1 Active not recruiting
NCT06662227 2026-05-07
Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
Wondercel Biotech (ShenZhen)
Phase EARLY_PHASE1 Suspended
NCT07563543 2026-05-04
RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1 Not yet recruiting
NCT07546630 2026-04-29
Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences
Phase EARLY_PHASE1 Not yet recruiting
NCT07548697 2026-04-23
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1 Recruiting
NCT07376642 2026-03-30
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Suzhou Immunofoco Biotechnology Co., Ltd
Phase EARLY_PHASE1 Recruiting
NCT07168291 2025-09-17
Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
First Affiliated Hospital Xi'an Jiaotong University
Phase EARLY_PHASE1 Not yet recruiting
NCT06446128 2025-08-21
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)
Shanghai Cell Therapy Group Co.,Ltd
Phase EARLY_PHASE1 Recruiting
NCT05779930 2025-08-15
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
Nationwide Children's Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT06976437 2025-07-10
A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
Affiliated Hospital of Jiangsu University
Phase EARLY_PHASE1 Recruiting
NCT07048353 2025-07-02
CAR-T，MTD
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
Phase EARLY_PHASE1 Not yet recruiting